A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint Therapies

Abayasiriwardana K
Pfizer
May 14, 2025
Mol Cancer Ther
https://pubmed.ncbi.nlm.nih.gov/40366350

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/40366350

Research summary

This study evaluates PF-07260437, a B7-H4xCD3 bispecific antibody, which redirects T cells to kill B7-H4+ breast cancer cells. Significant tumor regression was observed in humanized preclinical models, particularly when combined with anti-PD-1, palbociclib, or fulvestrant. The bispecific increased CD8+ T cell infiltration and enhanced immune-mediated tumor killing.

Key outcome of the study

PF-07260437 shows strong anti-tumor efficacy, especially in combination with standard therapies, and promotes T cell infiltration and immune activation in B7-H4+ tumors.

Model

Humanized CD3ε Knockin mouse model generated by genOway, used to assess PF-07260437 in an immunocompetent T cell context; combined with B7-H4+ tumor models.

TARGET:
CD3E, VTCN1
Synonyms:
CD3 epsilon, B7-H4, B7S1, B7x

Keywords

Breast cancer, Immunotherapy, CD3 bispecifics, T cell redirection, Combination therapy

Technical specifications

Humanized Knockin, CD3ε, Bispecific antibody, T cell engager

Related products

Catalogue product

genO‑hCD3ε

genO‑hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

Customized product

No items found.

Catalogue product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe